First preventative vaccine against lung cancer begins human trials in 2026

Universidade of The technology uses a viral vector similar to that of the AstraZeneca vaccine against Covid-19 to deliver DNA that activates an immune response against lung cells with initial mutations. The clinical trial will involve 590 participants in phases 1 and 2, with an initial focus on safety and preliminary signs of efficacy.
Financing of £2 million (around R$13 million) allows the project to move forward, which has already demonstrated positive results in laboratory tests. The vaccine targets the NY-ESO-1 protein, a common marker for pre-tumor changes.
How technology operates in the body
The modified viral vector transports the DNA fragment to the cells. Ao reaches the cell nucleus, the material induces temporary production of the NY-ESO-1 protein.
This protein works as an alert for the immune system. Células T begin to recognize and eliminate lung cells that express the marker before tumor formation.
The mechanism creates specific immune surveillance in the lungs. Preclinical Testes indicated robust activation of cytotoxic T lymphocytes.
Initial audience for clinical trials
The first volunteers will be adults aged 50 to 80 with a history of surgically cured early-stage lung cancer.
People with lung nodules detected in screening and classified as intermediate risk will also participate.
- Patients operated on with positive margins or compromised lymph nodes
- Ex-smokers with more than 20 pack-years of consumption
- Individuals on Low Dose CT Scan Programs for Screening
The selection prioritizes those who are most likely to relapse in the next five years.

Stages planned for 2026 and 2027
Phase 1 starts with 30 volunteers and tests three different dosages. Researchers monitor adverse reactions for 90 days after each application.
In phase 2, 560 participants receive two doses four weeks apart. Metade of the group receives placebo for comparison.
Primary endpoints include specific T cell activation rate and incidence of serious adverse events. Resultados Phase 1 preliminaries are expected in the second half of 2026.
Epidemiological profile that justifies the development
Lung cancer records around 2.2 million new cases annually worldwide, according to data from Organização Mundial and Saúde.
In Brasil, Instituto Nacional of Câncer estimates 32 thousand new diagnoses for 2025. The disease maintains a five-year survival rate below 20% when diagnosed at an advanced stage.
The incidence increases among non-smokers, especially women, due to exposure to pollutants and genetic factors.
Positioning of Brazilian experts
Oncologists consulted evaluate the project as promising, but emphasize that it is still in its early stages.
The immunological response observed in the laboratory is not always reproduced in humans with the same intensity. Fatores as advanced age and comorbidities may reduce effectiveness.
Defining the final target audience will depend on the results of phases 2 and 3. Active Fumantes, former heavy smokers and carriers of specific genetic mutations are likely candidates.
The vaccine does not replace smoking cessation or CT screening. Ela would be a complement to already identified high-risk groups.
Next steps for the British consortium
Recruitment begins in early 2026 at centers in Reino Unido. Outros European countries must join the study in phase 2b.
If the safety data is positive, phase 3 could involve up to 3,000 participants from 2028. Regulatory approval would only occur after all stages have been completed.






